• A small, privately held clinical stage biotech sought to quantify the dynamics at play in a mass market cardiovascular indication in the US, with an emphasis on a recently launched franchise that they would be competing against with their RNA technology

• Their goal was to inform a launch forecast, clinical development decisions, and help in partnership negotiations

• Designed and executed an Internet survey with academic and community cardiologists in the US
• Used conjoint to create a user-friendly “what-if” scenario modeling tool to forecast scenarios across various patient and physician segments in 2 and 3 and 4 product markets
• Uncovered the dynamics behind a key relationship between 2 product attributes that had previously been hidden, leading to a re-thinking of clinical development

• Identified key attributes at play; structured conjoint scheme to run parallel studies spanning 3 patient types
• Designed a concise conjoint grid spanning attributes and levels of highest competitive importance
• Modeled a series of 2, 3, and 4 product markets across various patient types, uncovering unexpected pockets of opportunity
• Conducted sensitivity analyses to uncover hidden relationships between product attributes across segments
• Integrated sensitivity analyses across patient segments in visually compelling ways
• Synthesized data into a series of actionable insights; uncovered the dynamics behind a key relationship between 2 attributes that had previously been hidden, leading to a re-thinking of clinical development

• A mid-sized pharmaceutical client was in a quandary: they had a compelling asset with a well-defined clinical target, but had only a very rough estimate of the market size due to poor epidemiology coverage in the medical literature
• To advance partnership discussions, they sought to estimate the global genetic and diagnosed prevalence of this rare condition using an efficient, cost-effective custom methodology

• Conducted a 10-minute survey among n=500 “all-comers” across 3 specialties and 4 countries; supplemented this with rigorous secondary research
• Quantitative techniques were used to extrapolate prevalence to real-world while stratifying for patient age and severity and eliminating duplicate patients who are comanaged by multiple physicians
• Aquest arrived at an accurate figure for global diagnosed prevalence that allowed the client to adequately forecast and advance partnership discussions

• Survey provided a quantitative understanding of the patient journey which allowed us to correct for double counting at the country-level
• Using a battery of diagnostic questions we were able to estimate both the genetic prevalence and the diagnosed prevalence to high accuracy
• We concluded with high precision (and by geography) that doctors treat 8 unique patients in a 3-month period
• A final summary of prevalence by patient segment and by country was obtained, allowing the client to adequately forecast and advance partnership discussions

A mid-sized pharmaceutical company decided to take a fresh look at potential agents to in-license. Their question was simple yet challenging: are there any attractive opportunities among compounds currently marketed in ex-US territories that have never been reviewed by the FDA? Aquest built a sophisticated data gathering and screening tool (keying off such value drivers as strength of clinical evidence, therapeutic area attractiveness, commercial potential, regulatory pathway risk, and IP status). A process that started with over 10,000 compounds resulted in a prioritized list of 10 promising agents, several of which were selected for more intensive diligence.